Suzhou Xinnuowei Pharmaceutical Technology

CSPC Innovation Pharmaceutical, often referred to as Xinnuowei, is a core subsidiary of the CSPC Pharmaceutical Group focused on the development, manufacturing, and commercialization of innovative drugs and high-end health products. Historically known for its dominant position in the caffeine and vitamin-based functional food additives market, the company has aggressively pivoted toward high-growth biotech sectors, including oncology and metabolic diseases. Through strategic acquisitions, such as the integration of CSPC Megalith Biopharmaceutical, the company has expanded its pipeline to include advanced modalities like antibody-drug conjugates (ADCs) and mRNA vaccines. Headquartered in Shijiazhuang with significant operations in Suzhou, the company leverages a robust R&D infrastructure to transition from a chemical manufacturer to a leading innovation-driven biopharmaceutical player.